Lorecivivint (LOR), an intra-articular (IA), small-molecule CLK2/DYRK1A inhibitor that modulates the Wnt pathway, has been shown in animal studies to induce chondrogenesis, protect cartilage, and reduce inflammation and, thereby, improve joint health. 1 Current therapeutic options focus on alleviating symptoms and pain rather than disease modification.
Posttraumatic OA accounts for approximately 12% of all OA cases. Objectives: Osteoarthritis (OA) is characterized by increased cartilage thinning, bone remodeling, and inflammation. 1 Formerly Biosplice Therapeutics, Inc., 2 Biosplice Therapeutics, Inc., San Diego, CA, United States. Tim Seo 1, Vishal Deshmukh 2, and Yusuf Yazici 2. PANLAR202 LORECIVIVINT, AN INTRA-ARTICULAR, SMALL-MOLECULE CLK2/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, PROVIDES CARTILAGE-PROTECTIVE EFFECTS IN AN ANIMAL MODEL OF POST-TRAUMATIC OSTEOARTHRITIS
0 kommentar(er)
